6185 related articles for article (PubMed ID: 19322513)
1. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
2. Hormonal diagnosis of GH hypersecretory states.
Grottoli S; Gasco V; Ragazzoni F; Ghigo E
J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of leptin levels in plasma and their reliance on other hormonal factors affecting tissue fat levels in people with various levels of endogenous cotisol].
Robaczyk MG
Ann Acad Med Stetin; 2002; 48():283-300. PubMed ID: 14601484
[TBL] [Abstract][Full Text] [Related]
4. Homocysteine levels in acromegaly patients.
Hekimsoy Z; Ozmen B; Ulusoy S
Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
[TBL] [Abstract][Full Text] [Related]
5. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
Petersen KR
Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
[TBL] [Abstract][Full Text] [Related]
7. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Bastemir M; Akin F; Yaylali GF
Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
[TBL] [Abstract][Full Text] [Related]
8. Low serum IGF-I/GH ratio is associated with abnormal glucose tolerance in acromegaly.
Fukuoka H; Takahashi Y; Iida K; Kudo T; Nishizawa H; Imanaka M; Takeno R; Iguchi G; Takahashi K; Okimura Y; Kaji H; Chihara K
Horm Res; 2008; 69(3):165-71. PubMed ID: 18219220
[TBL] [Abstract][Full Text] [Related]
9. Insulin sensitivity in growth hormone (GH)-deficient adults and effect of GH replacement therapy.
Alford FP; Hew FL; Christopher MC; Rantzau C
J Endocrinol Invest; 1999; 22(5 Suppl):28-32. PubMed ID: 10442567
[TBL] [Abstract][Full Text] [Related]
10. Type II diabetes and syndrome X. Pathogenesis and glycemic management.
Karam JH
Endocrinol Metab Clin North Am; 1992 Jun; 21(2):329-50. PubMed ID: 1612069
[TBL] [Abstract][Full Text] [Related]
11. Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance.
Eriksson JG; Lehtovirta M; Ehrnström B; Salmela S; Groop L
J Intern Med; 2006 Jun; 259(6):553-60. PubMed ID: 16704555
[TBL] [Abstract][Full Text] [Related]
12. Effects of growth hormone on glucose metabolism.
Møller N; Jørgensen JO; Abildgård N; Orskov L; Schmitz O; Christiansen JS
Horm Res; 1991; 36 Suppl 1():32-5. PubMed ID: 1806481
[TBL] [Abstract][Full Text] [Related]
13. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus.
Rader DJ
Am J Med; 2007 Mar; 120(3 Suppl 1):S12-8. PubMed ID: 17320517
[TBL] [Abstract][Full Text] [Related]
14. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
[TBL] [Abstract][Full Text] [Related]
15. New therapeutic agents for the treatment of NIDDM.
Kuehnle HF
Exp Clin Endocrinol Diabetes; 1996; 104(2):93-101. PubMed ID: 8740931
[TBL] [Abstract][Full Text] [Related]
16. On the pathophysiology of late onset non-insulin dependent diabetes mellitus. Current controversies and new insights.
Vaag A
Dan Med Bull; 1999 Jun; 46(3):197-234. PubMed ID: 10421979
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
18. [Amylin as an additional possible pathogenic factor in NIDDM and the insulin resistance syndrome].
Hrnciar J
Vnitr Lek; 1996 Aug; 42(8):557-60. PubMed ID: 8967027
[TBL] [Abstract][Full Text] [Related]
19. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control.
Ahn CW; Kim CS; Nam JH; Kim HJ; Nam JS; Park JS; Kang ES; Cha BS; Lim SK; Kim KR; Lee HC; Huh KB
Clin Endocrinol (Oxf); 2006 Apr; 64(4):444-9. PubMed ID: 16584518
[TBL] [Abstract][Full Text] [Related]
20. [Diabetes secondary to endocrinolopathies].
Suzuki S
Nihon Rinsho; 1996 Oct; 54(10):2709-14. PubMed ID: 8914432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
